The Shotlee Journal
Browse Shotlee articles about Weight Management.
Showing 9 / 872 Weight Management articles
A new study shows that some patients on GLP-1 drugs like Wegovy can space out injections every other week or longer and still keep weight off. Led by Dr. Mitch Biermann at Scripps Clinic, the research followed 34 patients who maintained health gains after reducing frequency. Experts say this reframes long-term obesity treatment discussions.
Deutsche Bank has reiterated its Buy rating on Eli Lilly stock, highlighting robust GLP-1 prescription growth despite recent dips. With Mounjaro and Zepbound leading, prescriptions rebounded 7% week-over-week, underscoring Lilly's dominance in the diabesity market. Discover the latest data on oral Wegovy and emerging oral GLP-1s like orforglipron.
Irish pharmaceutical exports hit a record €139bn in 2025, with GLP-1 weight-loss drugs from Eli Lilly and Novo Nordisk driving 20% of total goods exports. Eli Lilly's facilities in Ireland and massive US investments underscore the sector's growth. This boom promises faster access to innovative metabolic treatments for patients.
Novo Nordisk has received a second FDA untitled letter in weeks, this time targeting an Ozempic digital ad that parodies Apple's 'Get a Mac' campaign with actors Justin Long and John Hodgman. The regulator cites misleading presentations of Ozempic's indications and unsubstantiated superiority claims over other GLP-1s. Understand the concerns and what it means for patients seeking accurate information on these therapies.
Just 20% of youth eligible for GLP-1 receptor agonists due to obesity are actually prescribed these medications, according to a recent Pediatrics study. Prescribing favors older adolescents with higher BMI and specific racial groups, but interruptions due to cost affect nearly two-thirds. This highlights gaps in access to promising obesity treatments for teens.
Weight-loss injections like Ozempic and Wegovy, containing semaglutide, may protect the heart from severe tissue damage after a heart attack, according to new research. The study reveals how this GLP-1 medication prevents the dangerous 'no-reflow' phenomenon. Experts suggest it could even be administered by paramedics en route to the hospital.
Despite fears that surging GLP-1 weight loss drugs would slash snack sales, new USDA data shows units holding steady at over 10 billion annually through 2024. Prescriptions rose from 0.5% to 2% of adults, yet food consumption patterns surprise economists. Discover the resilience, consumer shifts, and future outlook.
Obesity levels have plateaued in Denmark at 18.5% among adults and older teens in 2025, unchanged from 2021 after years of rises from 13.6% in 2010. Novo Nordisk launched Wegovy there in late 2022, with 270,000 users—nearly 5% of the population—potentially shifting trends away from 32% by 2040 projections. Experts credit GLP-1 drugs like Wegovy and Ozempic alongside lifestyle factors.
A man who shed six stone on Mounjaro shares his dramatic transformation from 123kg, but warns of 'horrible' side effects like chronic vomiting and dehydration no one mentioned. Despite the challenges, he reduced hypertension meds and gained food control. Discover his full story and management strategies.
